It's for different reasons.
One of the reasons is that we don't have the institutional capacity to contain the cost of drugs. For me, one of the main reasons is not having a universal pharmacare system, as compared to European countries. It's a huge issue.
In 1987, the way we decided to regulate the price of patented drugs was to take a basket of seven countries, the ones that had the most intensive research and development as compared to sales, and cap the price based on the median of these seven countries. That was the system in place in 1987 through the PMPRB, the Patented Medicine Prices Review Board. Inside this basket you have the four most expensive countries in the world, so we're capping the price based on the four most expensive countries in the world.